Oleander Medical Technologies

Oleander Medical Technologies is pioneering a novel, physics-based oncology platform called Targeted Osmotic Lysis (TOL), which exploits the overexpression of sodium channels in advanced cancer cells. The treatment involves administering digoxin to block sodium-potassium pumps, followed by application of a pulsed electric field to open sodium channels, causing cancer cells to swell and burst osmotically. Led by a team with deep scientific and operational expertise, the company is advancing this pre-clinical program with the potential to address invasive, late-stage cancers that are poorly served by current therapies. If successful, TOL could offer a new treatment paradigm with a favorable safety profile due to its selective mechanism.

Targeted Osmotic Lysis (TOL): A two-step platform combining a generic sodium-potassium pump blocker (digoxin) with a proprietary pulsed electric field device. It exploits the overexpression of sodium channels in advanced cancer cells to induce selective cell death via osmotic lysis.

TOL operates in the physical oncology space, distinct from most pharmacologic therapies. It may face indirect competition from tumor treating fields (Optune) and other ablation techniques. Its primary competitive advantage is a novel, potentially universal mechanism targeting a biophysical vulnerability of advanced cancer cells.